Exploring the Severity Strata of Disease Activity and Repigmentation in Vitiligo Based on Validated Physician Global Assessment (PGA) Scores

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 11

PMID 38731208

Authors

Nanja van Geel

Liesbeth Delbaere

Laura Mertens

Virginie Vandaele

Lien Depaepe

Jerome Van Causenbroeck

Sofie De Schepper

Laura Van Coile

Astrid Van Reempts

Ann-Sophie De Vos

Jorien Papeleu

Isabelle Hoorens

Albert Wolkerstorfer

Reinhart Speeckaert

Affiliations

Soon will be listed here.

Abstract

There is currently no guidance on how to interpret the global degrees of activity (worsening) and repigmentation (improvement) in vitiligo. Stratification into global degrees can be completed for static evaluations (e.g., visible disease activity signs) and dynamic assessments (e.g., evolution over time). For the latter, the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS) were recently validated. : In the current study, a Physician Global Assessment (PGA) for disease activity (worsening) and repigmentation (improvement) was evaluated for validity (construct) and reliability (inter- and intrarater) based on a photo set of 66 patients. Subsequently, the PGA activity (worsening) and repigmentation (improvement) were used to stratify the Vitiligo Extent Score plus (VESplus), VDAS or VDIS into three global categories (slightly, moderately and much worse/improved), based on ROC analysis. : For the VESplus, cut-off values for the categories 'slightly, moderately and much worse' were >0.3%, >27.71% and >128.75% BSA (relative changes in the affected total BSA), respectively. For the categories 'slightly, moderately and much improved', they were >0%, >4.87% and >36.88% BSA (relative changes in the affected total BSA), respectively. The optimal cut-off values of the number of active (VDAS) body areas were >0 areas for slightly worse, >2 areas for moderately worse and >7 for much worse. For VDIS, the cut-off values for slightly improved and moderately improved were >0 and >1. For VDAS and VDIS, the cut-off points were >0.5, >3, >9.5 and >0.5 and >1.5, respectively. The results should be interpreted with caution in patients with extensive vitiligo due to the rather limited disease extent of the included patient population (VESplus (median: 3.2%)). : This research will aid in the development of more detailed international definitions.

References

Terwee C, Peipert J, Chapman R, Lai J, Terluin B, Cella D . Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021; 30(10):2729-2754. PMC: 8481206. DOI: 10.1007/s11136-021-02925-y. View

Sassi F, Cazzaniga S, Tessari G, Chatenoud L, Reseghetti A, Marchesi L . Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol. 2008; 159(5):1186-91. DOI: 10.1111/j.1365-2133.2008.08793.x. View

van Geel N, Depaepe L, Vandaele V, Mertens L, Van Causenbroeck J, de Schepper S . Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS). J Eur Acad Dermatol Venereol. 2022; 36(8):1334-1341. PMC: 9543188. DOI: 10.1111/jdv.18134. View

Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D . The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010; 19(4):539-49. PMC: 2852520. DOI: 10.1007/s11136-010-9606-8. View

Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D . The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010; 63(7):737-45. DOI: 10.1016/j.jclinepi.2010.02.006. View

van Geel N, Speeckaert R, Taieb A, Ezzedine K, Lim H, Pandya A . Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023; 37(11):2173-2184. DOI: 10.1111/jdv.19451. View

van Geel N, Wolkerstorfer A, Ezzedine K, Pandya A, Bekkenk M, Grine L . Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell Melanoma Res. 2019; 32(5):728-733. DOI: 10.1111/pcmr.12784. View

van Geel N, Wolkerstorfer A, Lommerts J, Ezzedine K, Eleftheriadou V, Hamzavi I . Validation study of the Vitiligo Extent Score-plus. J Am Acad Dermatol. 2017; 78(5):1013-1015. DOI: 10.1016/j.jaad.2017.11.032. View

van Geel N, Bekkenk M, Lommerts J, Ezzedine K, Harris J, Hamzavi I . The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. J Am Acad Dermatol. 2018; 79(2):369-371. DOI: 10.1016/j.jaad.2017.12.070. View

10.

Charman C, Venn A, Ravenscroft J, Williams H . Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013; 169(6):1326-32. PMC: 3920642. DOI: 10.1111/bjd.12590. View

11.

Singh S, Khandpur S, Sharma V, Ramam M . Comparison of efficacy and side-effect profile of oral PUVA vs. oral PUVA sol in the treatment of vitiligo: a 36-week prospective study. J Eur Acad Dermatol Venereol. 2012; 27(11):1344-51. DOI: 10.1111/jdv.12002. View

12.

Cavalie M, Ezzedine K, Fontas E, Montaudie H, Castela E, Bahadoran P . Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2014; 135(4):970-974. DOI: 10.1038/jid.2014.527. View